Cervical Dysplasia - Pipeline Review, H2 2014

Date: December 31, 2014
Pages: 66
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CF4E5338988EN
Leaflet:

Download PDF Leaflet

Cervical Dysplasia - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Cervical Dysplasia - Pipeline Review, H2 2014’, provides an overview of the Cervical Dysplasia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cervical Dysplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Dysplasia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Cervical Dysplasia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cervical Dysplasia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cervical Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cervical Dysplasia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cervical Dysplasia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cervical Dysplasia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Cervical Dysplasia Overview
Therapeutics Development
Pipeline Products for Cervical Dysplasia - Overview
Pipeline Products for Cervical Dysplasia - Comparative Analysis
Cervical Dysplasia - Therapeutics under Development by Companies
Cervical Dysplasia - Therapeutics under Investigation by Universities/Institutes
Cervical Dysplasia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Cervical Dysplasia - Products under Development by Companies
Cervical Dysplasia - Products under Investigation by Universities/Institutes
Cervical Dysplasia - Companies Involved in Therapeutics Development
CEL-SCI Corporation
Helix BioPharma Corp.
Inovio Pharmaceuticals, Inc.
PDS Biotechnology Corporation
VLPbio
Cervical Dysplasia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CerviVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CIGB-228 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alpha-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leukocyte Interleukin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDS-0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cervical Dysplasia - Recent Pipeline Updates
Cervical Dysplasia - Dormant Projects
Cervical Dysplasia - Discontinued Products
Cervical Dysplasia - Product Development Milestones
Featured News & Press Releases
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology
Feb 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune Cancer Immunotherapy Platform in a Phase 1 Clinical Trial
Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study
May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer
Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application
Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines
Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress
Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine
May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Cervical Dysplasia, H2 2014
Number of Products under Development for Cervical Dysplasia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Cervical Dysplasia - Pipeline by CEL-SCI Corporation, H2 2014
Cervical Dysplasia - Pipeline by Helix BioPharma Corp., H2 2014
Cervical Dysplasia - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014
Cervical Dysplasia - Pipeline by PDS Biotechnology Corporation, H2 2014
Cervical Dysplasia - Pipeline by VLPbio, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Cervical Dysplasia Therapeutics - Recent Pipeline Updates, H2 2014
Cervical Dysplasia - Dormant Projects, H2 2014
Cervical Dysplasia - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Cervical Dysplasia, H2 2014
Number of Products under Development for Cervical Dysplasia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

CEL-SCI Corporation
Helix BioPharma Corp.
Inovio Pharmaceuticals, Inc.
PDS Biotechnology Corporation
VLPbio
Skip to top


Cervical Dysplasia - Pipeline Review, H1 2015 US$ 1,600.00 May, 2015 · 56 pages
Bronchopulmonary Dysplasia - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 64 pages
Bronchopulmonary Dysplasia - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 63 pages
Cervical Dysplasia - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Cervical Cancer - Pipeline Review, 2015 US$ 3,200.00 Oct, 2015 · 71 pages

Ask Your Question

Cervical Dysplasia - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: